# A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

> **NCT06858696** · PHASE1 · RECRUITING · sponsor: **X4 Pharmaceuticals** · enrollment: 48 (estimated)

## Conditions studied

- Hepatic Insufficiency

## Interventions

- **DRUG:** Mavorixafor

## Key facts

- **NCT ID:** NCT06858696
- **Lead sponsor:** X4 Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-28
- **Primary completion:** 2026-03
- **Final completion:** 2026-04
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06858696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06858696, "A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06858696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*